Meeting
2024 ASCO Annual Meeting
Panel Question and Answer
Presenter
Panel Discussion
ASCO
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Education Session
Session Title
The Lancet Commission on Women, Power, and Cancer: North American Launch
Track
Special Sessions,Medical Education and Professional Development,Disparities/Health Equity,Global Health
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.
Speaker: Shubham Pant, MD, MBBS
Videos & Slides
2024 ASCO Annual Meeting
Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment.
Speaker: Jeesun Yoon, MD
Videos & Slides
2024 ASCO Annual Meeting
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.
Speaker: Thatcher Ross Heumann, MD, MPH
Videos & Slides
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
Speaker: John Ebben, MD, PhD